Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Februar 2025

Genmab — Februar 2025

Planlagt Fastgjort Låst Flyttet Genmab
699 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • L Offline
    L Offline
    lahn1
    wrote on sidst redigeret af
    #501

    yes Jan eluted to that point. Treatment is al about combination.

    1 Reply Last reply
    0
    • L Offline
      L Offline
      lahn1
      wrote on sidst redigeret af
      #502

      Ja enten disrupter du dig selv eller også disrupter andre dig, period !

      1 Reply Last reply
      0
      • S Offline
        S Offline
        Sukkeralf
        wrote on sidst redigeret af
        #503

        Yes but if Genmab is doing th clinical trials they probably need to buy tec and tal - so its so much easier if Janssen takes the option

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #504

          it is definitely easier; i think we established that long time ago. And best for the short term share price reaction. And my blood pressure... (whether JNJ would or would not sponsor the Tec or Tal , is really a
          minor issue i would think)

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #505

            New trial - eal-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma / EpcoReal: A Multi-country, Prospective Observational Study of Epcoritamab in NHL Comprising Two Patient Cohorts (3L+ (D)LBCL and 3L+ FL) https://clinicaltrials.gov/study/NCT06830759

            1 Reply Last reply
            0
            • G Offline
              G Offline
              gentogen
              wrote on sidst redigeret af
              #506

              Daratumumab is increasingly used in first-line, and soon patients that relapse while on daratumumab will become a common challenge.

              1 Reply Last reply
              0
              • G Offline
                G Offline
                gentogen
                wrote on sidst redigeret af
                #507

                Link Preview Image
                ScienceDirect

                favicon

                (www.sciencedirect.com)

                1 Reply Last reply
                0
                • P Offline
                  P Offline
                  ProinvestorNEWS
                  wrote on sidst redigeret af
                  #508

                  Teknisk: Genmab i brud op gennem vigtige modstande, fortsætter op i USA https://proinvestor.com/investornyt/1279889/teknisk-genmab-i-brud-op-gennem-vigtige-modstande-fortsaetter-op-i-usa

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #509

                    Leo Habets
                    @L_Habets
                    Daratumumab Seit einiger Zeit behandeln wir Post, COVID, Post Vac und MEC FS Patienten mit Daratumumab wir haben jetzt insgesamt sieben Patienten in der Behandlung https://x.com/L_Habets/status/1891069465686634514 https://x.com/L_Habets/status/1891210734530400443

                    1 Reply Last reply
                    0
                    • B Offline
                      B Offline
                      bikube
                      wrote on sidst redigeret af
                      #510

                      die Behandlung ist teuer, die kostet 20000€ fyr 4 gaben. Det er vist første gang, jeg har set en kontant pris på Dara.

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #511

                        TipRanks
                        Feb. 19, 2025, 01:35 AM
                        In a report released today, Emily Field from Barclays maintained a Buy rating on Genmab A/S
                        , with a price target of DKK2,100.00.

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #512

                          looks like we will get an Acasunlimab Poster at the European Lung Cancer Congress at the end of the March https://cslide.ctimeetingtech.com/coasis_21204/attendee/confcal/presentation/list?q=acasunlimab Also a few for amivantamab, also orals

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #513

                            Kempen erhöht Kursziel für Genmab auf DKK 3.070 (2.950) und bekräftigt Kaufen - BN
                            Am 19. Februar 2025 https://de.marketscreener.com/kurs/aktie/GENMAB-A-S-63733191/news/Kempen-erhoht-Kursziel-fur-Genmab-auf-DKK-3-070-2-950-und-bekraftigt-Kaufen-BN-49100440/

                            1 Reply Last reply
                            0
                            • BulderB Offline
                              BulderB Offline
                              Bulder
                              wrote on sidst redigeret af
                              #514

                              Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano and Chief Development Officer Judith Klimovsky will participate in a fireside chat at the 45th Annual TD Cowen Health Care Conference, nå Winkel skal ikke med.

                              1 Reply Last reply
                              0
                              • P Offline
                                P Offline
                                ProinvestorNEWS
                                wrote on sidst redigeret af
                                #515

                                Hvordan ser fremtiden ud for forsvarsaktierne i en tid med mulige milliardinvesteringer i mange lande? Hør også om Genmabs kommende og vigtige afgørelse, kollapset i Bavarian Nordic samt meget andet i afsnit 262 af Investeringspodcasten. https://proinvestor.com/boards/124824

                                1 Reply Last reply
                                0
                                • royalR Offline
                                  royalR Offline
                                  royal
                                  wrote on sidst redigeret af
                                  #516

                                  Er lidt forvirret: 60 dage fra ca. 1. januar = Ultimo februar. 1. kvartal 2025 som Jan selv siger?

                                  1 Reply Last reply
                                  0
                                  • A Offline
                                    A Offline
                                    Aaanditsgone
                                    wrote on sidst redigeret af
                                    #517

                                    Hvis det er 60 arbejdsdage, passer det meget godt med slutningen af marts. Vi kender ikke den præcise deadine.

                                    1 Reply Last reply
                                    0
                                    • SolsenS Offline
                                      SolsenS Offline
                                      Solsen
                                      wrote on sidst redigeret af
                                      #518

                                      Shh der forhandles 😉

                                      1 Reply Last reply
                                      0
                                      • royalR Offline
                                        royalR Offline
                                        royal
                                        wrote on sidst redigeret af
                                        #519

                                        🙂

                                        1 Reply Last reply
                                        0
                                        • R Offline
                                          R Offline
                                          Raun
                                          wrote on sidst redigeret af
                                          #520

                                          Der skal ifølge aftalen komme et svar inden 1. marts.... - Dette bekræftede Helge også forleden dag.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper